nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirtazapine—ADRB2—chronic obstructive pulmonary disease	0.12	0.291	CbGaD
Mirtazapine—SLC6A4—chronic obstructive pulmonary disease	0.109	0.265	CbGaD
Mirtazapine—CYP1A2—chronic obstructive pulmonary disease	0.0992	0.241	CbGaD
Mirtazapine—HTR2A—chronic obstructive pulmonary disease	0.0837	0.203	CbGaD
Mirtazapine—ADRB2—Salbutamol—chronic obstructive pulmonary disease	0.0549	0.141	CbGbCtD
Mirtazapine—ADRB1—Salbutamol—chronic obstructive pulmonary disease	0.0541	0.139	CbGbCtD
Mirtazapine—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0416	0.107	CbGbCtD
Mirtazapine—ADRB2—Arformoterol—chronic obstructive pulmonary disease	0.0416	0.107	CbGbCtD
Mirtazapine—ADRB1—Formoterol—chronic obstructive pulmonary disease	0.041	0.105	CbGbCtD
Mirtazapine—ADRB1—Arformoterol—chronic obstructive pulmonary disease	0.041	0.105	CbGbCtD
Mirtazapine—CYP2C8—Montelukast—chronic obstructive pulmonary disease	0.0124	0.0318	CbGbCtD
Mirtazapine—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0114	0.0293	CbGbCtD
Mirtazapine—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0114	0.0293	CbGbCtD
Mirtazapine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0108	0.0276	CbGbCtD
Mirtazapine—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0104	0.0268	CbGbCtD
Mirtazapine—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0104	0.0268	CbGbCtD
Mirtazapine—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0093	0.0238	CbGbCtD
Mirtazapine—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.00876	0.0224	CbGbCtD
Mirtazapine—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.00865	0.0222	CbGbCtD
Mirtazapine—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.00591	0.0152	CbGbCtD
Mirtazapine—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.00564	0.0145	CbGbCtD
Mirtazapine—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.00503	0.0129	CbGbCtD
Mirtazapine—HTR2A—phrenic nerve—chronic obstructive pulmonary disease	0.00459	0.213	CbGeAlD
Mirtazapine—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.00295	0.00756	CbGbCtD
Mirtazapine—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.00279	0.00714	CbGbCtD
Mirtazapine—HTR7—pulmonary artery—chronic obstructive pulmonary disease	0.00267	0.124	CbGeAlD
Mirtazapine—HTR2A—pulmonary artery—chronic obstructive pulmonary disease	0.00167	0.0772	CbGeAlD
Mirtazapine—HTR3A—respiratory system—chronic obstructive pulmonary disease	0.000695	0.0322	CbGeAlD
Mirtazapine—SLC6A3—respiratory system—chronic obstructive pulmonary disease	0.000579	0.0268	CbGeAlD
Mirtazapine—SLC6A4—respiratory system—chronic obstructive pulmonary disease	0.00053	0.0245	CbGeAlD
Mirtazapine—ADRB1—connective tissue—chronic obstructive pulmonary disease	0.000483	0.0224	CbGeAlD
Mirtazapine—SLC6A2—respiratory system—chronic obstructive pulmonary disease	0.000467	0.0216	CbGeAlD
Mirtazapine—ADRB1—bronchus—chronic obstructive pulmonary disease	0.000452	0.0209	CbGeAlD
Mirtazapine—HTR7—respiratory system—chronic obstructive pulmonary disease	0.00045	0.0208	CbGeAlD
Mirtazapine—DRD2—respiratory system—chronic obstructive pulmonary disease	0.000425	0.0197	CbGeAlD
Mirtazapine—HTR2B—smooth muscle tissue—chronic obstructive pulmonary disease	0.000423	0.0196	CbGeAlD
Mirtazapine—HTR7—connective tissue—chronic obstructive pulmonary disease	0.000396	0.0183	CbGeAlD
Mirtazapine—HTR3A—lung—chronic obstructive pulmonary disease	0.000369	0.0171	CbGeAlD
Mirtazapine—HTR7—smooth muscle tissue—chronic obstructive pulmonary disease	0.000362	0.0168	CbGeAlD
Mirtazapine—CYP1A2—respiratory system—chronic obstructive pulmonary disease	0.000359	0.0166	CbGeAlD
Mirtazapine—ADRA2C—bronchus—chronic obstructive pulmonary disease	0.00034	0.0157	CbGeAlD
Mirtazapine—HRH1—respiratory system—chronic obstructive pulmonary disease	0.000336	0.0155	CbGeAlD
Mirtazapine—HTR7—trachea—chronic obstructive pulmonary disease	0.000332	0.0154	CbGeAlD
Mirtazapine—SLC6A3—lung—chronic obstructive pulmonary disease	0.000307	0.0142	CbGeAlD
Mirtazapine—ADRA2C—trachea—chronic obstructive pulmonary disease	0.000306	0.0141	CbGeAlD
Mirtazapine—HRH1—connective tissue—chronic obstructive pulmonary disease	0.000296	0.0137	CbGeAlD
Mirtazapine—ADRB1—lung—chronic obstructive pulmonary disease	0.000291	0.0135	CbGeAlD
Mirtazapine—ADRA2A—connective tissue—chronic obstructive pulmonary disease	0.00029	0.0134	CbGeAlD
Mirtazapine—Epinastine—HTR2A—chronic obstructive pulmonary disease	0.000282	0.331	CrCbGaD
Mirtazapine—SLC6A4—lung—chronic obstructive pulmonary disease	0.000282	0.013	CbGeAlD
Mirtazapine—HTR2A—respiratory system—chronic obstructive pulmonary disease	0.000281	0.013	CbGeAlD
Mirtazapine—HTR2B—lung—chronic obstructive pulmonary disease	0.000279	0.0129	CbGeAlD
Mirtazapine—ADRA2A—bronchus—chronic obstructive pulmonary disease	0.000272	0.0126	CbGeAlD
Mirtazapine—HRH1—smooth muscle tissue—chronic obstructive pulmonary disease	0.000271	0.0125	CbGeAlD
Mirtazapine—HRH1—trachea—chronic obstructive pulmonary disease	0.000248	0.0115	CbGeAlD
Mirtazapine—SLC6A2—lung—chronic obstructive pulmonary disease	0.000248	0.0115	CbGeAlD
Mirtazapine—HTR2A—connective tissue—chronic obstructive pulmonary disease	0.000247	0.0114	CbGeAlD
Mirtazapine—ADRA2A—trachea—chronic obstructive pulmonary disease	0.000244	0.0113	CbGeAlD
Mirtazapine—HTR7—lung—chronic obstructive pulmonary disease	0.000239	0.0111	CbGeAlD
Mirtazapine—HTR2A—smooth muscle tissue—chronic obstructive pulmonary disease	0.000226	0.0105	CbGeAlD
Mirtazapine—DRD2—lung—chronic obstructive pulmonary disease	0.000226	0.0105	CbGeAlD
Mirtazapine—ADRA2C—lung—chronic obstructive pulmonary disease	0.00022	0.0102	CbGeAlD
Mirtazapine—Mianserin—SLC6A4—chronic obstructive pulmonary disease	0.000212	0.25	CrCbGaD
Mirtazapine—HTR2A—trachea—chronic obstructive pulmonary disease	0.000207	0.00959	CbGeAlD
Mirtazapine—Mianserin—CYP1A2—chronic obstructive pulmonary disease	0.000193	0.227	CrCbGaD
Mirtazapine—CYP1A2—lung—chronic obstructive pulmonary disease	0.000191	0.00882	CbGeAlD
Mirtazapine—HRH1—lung—chronic obstructive pulmonary disease	0.000178	0.00825	CbGeAlD
Mirtazapine—ADRA2A—lung—chronic obstructive pulmonary disease	0.000175	0.00811	CbGeAlD
Mirtazapine—Mianserin—HTR2A—chronic obstructive pulmonary disease	0.000163	0.192	CrCbGaD
Mirtazapine—HTR2A—lung—chronic obstructive pulmonary disease	0.000149	0.00689	CbGeAlD
Mirtazapine—Myalgia—Salbutamol—chronic obstructive pulmonary disease	9.97e-05	0.000839	CcSEcCtD
Mirtazapine—Urticaria—Tiotropium—chronic obstructive pulmonary disease	9.97e-05	0.000839	CcSEcCtD
Mirtazapine—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	9.94e-05	0.000837	CcSEcCtD
Mirtazapine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	9.94e-05	0.000836	CcSEcCtD
Mirtazapine—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	9.93e-05	0.000836	CcSEcCtD
Mirtazapine—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	9.93e-05	0.000836	CcSEcCtD
Mirtazapine—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	9.92e-05	0.000835	CcSEcCtD
Mirtazapine—Oedema—Montelukast—chronic obstructive pulmonary disease	9.92e-05	0.000835	CcSEcCtD
Mirtazapine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	9.88e-05	0.000832	CcSEcCtD
Mirtazapine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	9.88e-05	0.000832	CcSEcCtD
Mirtazapine—Discomfort—Salbutamol—chronic obstructive pulmonary disease	9.85e-05	0.000829	CcSEcCtD
Mirtazapine—Infection—Montelukast—chronic obstructive pulmonary disease	9.85e-05	0.000829	CcSEcCtD
Mirtazapine—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	9.84e-05	0.000828	CcSEcCtD
Mirtazapine—Skin disorder—Formoterol—chronic obstructive pulmonary disease	9.84e-05	0.000828	CcSEcCtD
Mirtazapine—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	9.84e-05	0.000828	CcSEcCtD
Mirtazapine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	9.8e-05	0.000825	CcSEcCtD
Mirtazapine—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	9.75e-05	0.000821	CcSEcCtD
Mirtazapine—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	9.74e-05	0.00082	CcSEcCtD
Mirtazapine—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	9.73e-05	0.000818	CcSEcCtD
Mirtazapine—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	9.71e-05	0.000817	CcSEcCtD
Mirtazapine—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	9.71e-05	0.000817	CcSEcCtD
Mirtazapine—Skin disorder—Montelukast—chronic obstructive pulmonary disease	9.63e-05	0.000811	CcSEcCtD
Mirtazapine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	9.6e-05	0.000808	CcSEcCtD
Mirtazapine—Oedema—Salbutamol—chronic obstructive pulmonary disease	9.56e-05	0.000805	CcSEcCtD
Mirtazapine—Infection—Salbutamol—chronic obstructive pulmonary disease	9.5e-05	0.000799	CcSEcCtD
Mirtazapine—Hypotension—Formoterol—chronic obstructive pulmonary disease	9.46e-05	0.000796	CcSEcCtD
Mirtazapine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	9.46e-05	0.000796	CcSEcCtD
Mirtazapine—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	9.45e-05	0.000796	CcSEcCtD
Mirtazapine—Pruritus—Aminophylline—chronic obstructive pulmonary disease	9.41e-05	0.000792	CcSEcCtD
Mirtazapine—Shock—Salbutamol—chronic obstructive pulmonary disease	9.41e-05	0.000792	CcSEcCtD
Mirtazapine—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	9.39e-05	0.00079	CcSEcCtD
Mirtazapine—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	9.38e-05	0.000789	CcSEcCtD
Mirtazapine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	9.33e-05	0.000785	CcSEcCtD
Mirtazapine—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	9.32e-05	0.000784	CcSEcCtD
Mirtazapine—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	9.29e-05	0.000781	CcSEcCtD
Mirtazapine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	9.24e-05	0.000778	CcSEcCtD
Mirtazapine—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	9.24e-05	0.000778	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	9.22e-05	0.000776	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	9.22e-05	0.000776	CcSEcCtD
Mirtazapine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	9.16e-05	0.000771	CcSEcCtD
Mirtazapine—Insomnia—Formoterol—chronic obstructive pulmonary disease	9.16e-05	0.000771	CcSEcCtD
Mirtazapine—Anorexia—Salbutamol—chronic obstructive pulmonary disease	9.11e-05	0.000767	CcSEcCtD
Mirtazapine—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	9.1e-05	0.000766	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	9.04e-05	0.00076	CcSEcCtD
Mirtazapine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	9.03e-05	0.00076	CcSEcCtD
Mirtazapine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	9.03e-05	0.00076	CcSEcCtD
Mirtazapine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	9e-05	0.000758	CcSEcCtD
Mirtazapine—Somnolence—Formoterol—chronic obstructive pulmonary disease	9e-05	0.000758	CcSEcCtD
Mirtazapine—Insomnia—Montelukast—chronic obstructive pulmonary disease	8.97e-05	0.000755	CcSEcCtD
Mirtazapine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	8.93e-05	0.000752	CcSEcCtD
Mirtazapine—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	8.91e-05	0.00075	CcSEcCtD
Mirtazapine—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	8.91e-05	0.00075	CcSEcCtD
Mirtazapine—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	8.91e-05	0.000749	CcSEcCtD
Mirtazapine—Pruritus—Tiotropium—chronic obstructive pulmonary disease	8.88e-05	0.000747	CcSEcCtD
Mirtazapine—Somnolence—Montelukast—chronic obstructive pulmonary disease	8.82e-05	0.000742	CcSEcCtD
Mirtazapine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	8.8e-05	0.00074	CcSEcCtD
Mirtazapine—Weight increased—Prednisolone—chronic obstructive pulmonary disease	8.78e-05	0.000739	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	8.74e-05	0.000736	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	8.74e-05	0.000736	CcSEcCtD
Mirtazapine—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	8.73e-05	0.000735	CcSEcCtD
Mirtazapine—Fatigue—Formoterol—chronic obstructive pulmonary disease	8.73e-05	0.000735	CcSEcCtD
Mirtazapine—Fatigue—Arformoterol—chronic obstructive pulmonary disease	8.73e-05	0.000735	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	8.71e-05	0.000733	CcSEcCtD
Mirtazapine—Constipation—Formoterol—chronic obstructive pulmonary disease	8.66e-05	0.000729	CcSEcCtD
Mirtazapine—Constipation—Arformoterol—chronic obstructive pulmonary disease	8.66e-05	0.000729	CcSEcCtD
Mirtazapine—Pain—Formoterol—chronic obstructive pulmonary disease	8.66e-05	0.000729	CcSEcCtD
Mirtazapine—Pain—Arformoterol—chronic obstructive pulmonary disease	8.66e-05	0.000729	CcSEcCtD
Mirtazapine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	8.65e-05	0.000728	CcSEcCtD
Mirtazapine—Increased appetite—Prednisone—chronic obstructive pulmonary disease	8.63e-05	0.000726	CcSEcCtD
Mirtazapine—Amnesia—Prednisone—chronic obstructive pulmonary disease	8.63e-05	0.000726	CcSEcCtD
Mirtazapine—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	8.58e-05	0.000722	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	8.56e-05	0.000721	CcSEcCtD
Mirtazapine—Fatigue—Montelukast—chronic obstructive pulmonary disease	8.55e-05	0.00072	CcSEcCtD
Mirtazapine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	8.52e-05	0.000717	CcSEcCtD
Mirtazapine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	8.5e-05	0.000715	CcSEcCtD
Mirtazapine—Pain—Montelukast—chronic obstructive pulmonary disease	8.48e-05	0.000714	CcSEcCtD
Mirtazapine—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	8.48e-05	0.000713	CcSEcCtD
Mirtazapine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	8.46e-05	0.000712	CcSEcCtD
Mirtazapine—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	8.43e-05	0.000709	CcSEcCtD
Mirtazapine—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	8.42e-05	0.000708	CcSEcCtD
Mirtazapine—Rash—Aminophylline—chronic obstructive pulmonary disease	8.39e-05	0.000706	CcSEcCtD
Mirtazapine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	8.38e-05	0.000705	CcSEcCtD
Mirtazapine—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	8.36e-05	0.000703	CcSEcCtD
Mirtazapine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	8.34e-05	0.000702	CcSEcCtD
Mirtazapine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	8.34e-05	0.000702	CcSEcCtD
Mirtazapine—Headache—Aminophylline—chronic obstructive pulmonary disease	8.33e-05	0.000701	CcSEcCtD
Mirtazapine—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	8.31e-05	0.000699	CcSEcCtD
Mirtazapine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	8.3e-05	0.000698	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	8.28e-05	0.000697	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	8.28e-05	0.000697	CcSEcCtD
Mirtazapine—Lethargy—Prednisone—chronic obstructive pulmonary disease	8.27e-05	0.000696	CcSEcCtD
Mirtazapine—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	8.25e-05	0.000695	CcSEcCtD
Mirtazapine—Fatigue—Salbutamol—chronic obstructive pulmonary disease	8.24e-05	0.000694	CcSEcCtD
Mirtazapine—Pain—Salbutamol—chronic obstructive pulmonary disease	8.18e-05	0.000688	CcSEcCtD
Mirtazapine—Constipation—Salbutamol—chronic obstructive pulmonary disease	8.18e-05	0.000688	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	8.11e-05	0.000682	CcSEcCtD
Mirtazapine—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	8.11e-05	0.000682	CcSEcCtD
Mirtazapine—Urticaria—Formoterol—chronic obstructive pulmonary disease	8.04e-05	0.000677	CcSEcCtD
Mirtazapine—Urticaria—Arformoterol—chronic obstructive pulmonary disease	8.04e-05	0.000677	CcSEcCtD
Mirtazapine—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	8e-05	0.000674	CcSEcCtD
Mirtazapine—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	8e-05	0.000674	CcSEcCtD
Mirtazapine—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	8e-05	0.000674	CcSEcCtD
Mirtazapine—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	8e-05	0.000674	CcSEcCtD
Mirtazapine—Affect lability—Prednisone—chronic obstructive pulmonary disease	7.98e-05	0.000672	CcSEcCtD
Mirtazapine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	7.98e-05	0.000671	CcSEcCtD
Mirtazapine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	7.92e-05	0.000666	CcSEcCtD
Mirtazapine—Rash—Tiotropium—chronic obstructive pulmonary disease	7.91e-05	0.000666	CcSEcCtD
Mirtazapine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	7.9e-05	0.000665	CcSEcCtD
Mirtazapine—Nausea—Aminophylline—chronic obstructive pulmonary disease	7.9e-05	0.000665	CcSEcCtD
Mirtazapine—Urticaria—Montelukast—chronic obstructive pulmonary disease	7.88e-05	0.000663	CcSEcCtD
Mirtazapine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	7.88e-05	0.000663	CcSEcCtD
Mirtazapine—Headache—Tiotropium—chronic obstructive pulmonary disease	7.86e-05	0.000661	CcSEcCtD
Mirtazapine—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	7.86e-05	0.000661	CcSEcCtD
Mirtazapine—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	7.84e-05	0.00066	CcSEcCtD
Mirtazapine—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	7.84e-05	0.00066	CcSEcCtD
Mirtazapine—Face oedema—Prednisone—chronic obstructive pulmonary disease	7.83e-05	0.000659	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	7.82e-05	0.000658	CcSEcCtD
Mirtazapine—Mood swings—Prednisone—chronic obstructive pulmonary disease	7.68e-05	0.000646	CcSEcCtD
Mirtazapine—Urticaria—Salbutamol—chronic obstructive pulmonary disease	7.6e-05	0.000639	CcSEcCtD
Mirtazapine—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	7.56e-05	0.000636	CcSEcCtD
Mirtazapine—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	7.56e-05	0.000636	CcSEcCtD
Mirtazapine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	7.46e-05	0.000628	CcSEcCtD
Mirtazapine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	7.46e-05	0.000628	CcSEcCtD
Mirtazapine—Nausea—Tiotropium—chronic obstructive pulmonary disease	7.45e-05	0.000627	CcSEcCtD
Mirtazapine—Dry skin—Prednisone—chronic obstructive pulmonary disease	7.43e-05	0.000625	CcSEcCtD
Mirtazapine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	7.31e-05	0.000615	CcSEcCtD
Mirtazapine—Asthenia—Arformoterol—chronic obstructive pulmonary disease	7.26e-05	0.000611	CcSEcCtD
Mirtazapine—Asthenia—Formoterol—chronic obstructive pulmonary disease	7.26e-05	0.000611	CcSEcCtD
Mirtazapine—Pruritus—Formoterol—chronic obstructive pulmonary disease	7.16e-05	0.000603	CcSEcCtD
Mirtazapine—Pruritus—Arformoterol—chronic obstructive pulmonary disease	7.16e-05	0.000603	CcSEcCtD
Mirtazapine—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	7.15e-05	0.000602	CcSEcCtD
Mirtazapine—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	7.15e-05	0.000602	CcSEcCtD
Mirtazapine—Asthenia—Montelukast—chronic obstructive pulmonary disease	7.12e-05	0.000599	CcSEcCtD
Mirtazapine—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	7.05e-05	0.000594	CcSEcCtD
Mirtazapine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	7.04e-05	0.000593	CcSEcCtD
Mirtazapine—Pruritus—Montelukast—chronic obstructive pulmonary disease	7.02e-05	0.00059	CcSEcCtD
Mirtazapine—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	6.93e-05	0.000583	CcSEcCtD
Mirtazapine—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	6.93e-05	0.000583	CcSEcCtD
Mirtazapine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	6.9e-05	0.00058	CcSEcCtD
Mirtazapine—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	6.87e-05	0.000578	CcSEcCtD
Mirtazapine—Asthenia—Salbutamol—chronic obstructive pulmonary disease	6.86e-05	0.000577	CcSEcCtD
Mirtazapine—Sweating increased—Prednisone—chronic obstructive pulmonary disease	6.83e-05	0.000574	CcSEcCtD
Mirtazapine—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	6.79e-05	0.000571	CcSEcCtD
Mirtazapine—Pruritus—Salbutamol—chronic obstructive pulmonary disease	6.76e-05	0.000569	CcSEcCtD
Mirtazapine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	6.7e-05	0.000563	CcSEcCtD
Mirtazapine—Dizziness—Formoterol—chronic obstructive pulmonary disease	6.7e-05	0.000563	CcSEcCtD
Mirtazapine—Dizziness—Montelukast—chronic obstructive pulmonary disease	6.56e-05	0.000552	CcSEcCtD
Mirtazapine—Neutropenia—Prednisone—chronic obstructive pulmonary disease	6.55e-05	0.000551	CcSEcCtD
Mirtazapine—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	6.54e-05	0.00055	CcSEcCtD
Mirtazapine—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	6.45e-05	0.000543	CcSEcCtD
Mirtazapine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	6.44e-05	0.000542	CcSEcCtD
Mirtazapine—Vomiting—Formoterol—chronic obstructive pulmonary disease	6.44e-05	0.000542	CcSEcCtD
Mirtazapine—Rash—Formoterol—chronic obstructive pulmonary disease	6.38e-05	0.000537	CcSEcCtD
Mirtazapine—Rash—Arformoterol—chronic obstructive pulmonary disease	6.38e-05	0.000537	CcSEcCtD
Mirtazapine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	6.38e-05	0.000537	CcSEcCtD
Mirtazapine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	6.38e-05	0.000537	CcSEcCtD
Mirtazapine—Weight increased—Prednisone—chronic obstructive pulmonary disease	6.38e-05	0.000537	CcSEcCtD
Mirtazapine—Headache—Formoterol—chronic obstructive pulmonary disease	6.34e-05	0.000534	CcSEcCtD
Mirtazapine—Headache—Arformoterol—chronic obstructive pulmonary disease	6.34e-05	0.000534	CcSEcCtD
Mirtazapine—Weight decreased—Prednisone—chronic obstructive pulmonary disease	6.34e-05	0.000533	CcSEcCtD
Mirtazapine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	6.32e-05	0.000532	CcSEcCtD
Mirtazapine—Vomiting—Montelukast—chronic obstructive pulmonary disease	6.31e-05	0.000531	CcSEcCtD
Mirtazapine—Rash—Montelukast—chronic obstructive pulmonary disease	6.25e-05	0.000526	CcSEcCtD
Mirtazapine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	6.25e-05	0.000526	CcSEcCtD
Mirtazapine—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	6.23e-05	0.000525	CcSEcCtD
Mirtazapine—Headache—Montelukast—chronic obstructive pulmonary disease	6.21e-05	0.000523	CcSEcCtD
Mirtazapine—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	6.16e-05	0.000518	CcSEcCtD
Mirtazapine—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	6.12e-05	0.000515	CcSEcCtD
Mirtazapine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	6.08e-05	0.000512	CcSEcCtD
Mirtazapine—Malaise—Prednisolone—chronic obstructive pulmonary disease	6.06e-05	0.00051	CcSEcCtD
Mirtazapine—Vertigo—Prednisolone—chronic obstructive pulmonary disease	6.04e-05	0.000508	CcSEcCtD
Mirtazapine—Rash—Salbutamol—chronic obstructive pulmonary disease	6.03e-05	0.000507	CcSEcCtD
Mirtazapine—Syncope—Prednisolone—chronic obstructive pulmonary disease	6.03e-05	0.000507	CcSEcCtD
Mirtazapine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	6.02e-05	0.000507	CcSEcCtD
Mirtazapine—Nausea—Arformoterol—chronic obstructive pulmonary disease	6.01e-05	0.000506	CcSEcCtD
Mirtazapine—Nausea—Formoterol—chronic obstructive pulmonary disease	6.01e-05	0.000506	CcSEcCtD
Mirtazapine—Headache—Salbutamol—chronic obstructive pulmonary disease	5.99e-05	0.000504	CcSEcCtD
Mirtazapine—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	5.91e-05	0.000497	CcSEcCtD
Mirtazapine—Nausea—Montelukast—chronic obstructive pulmonary disease	5.89e-05	0.000496	CcSEcCtD
Mirtazapine—Convulsion—Prednisolone—chronic obstructive pulmonary disease	5.82e-05	0.00049	CcSEcCtD
Mirtazapine—Hypertension—Prednisolone—chronic obstructive pulmonary disease	5.8e-05	0.000488	CcSEcCtD
Mirtazapine—Bradycardia—Prednisone—chronic obstructive pulmonary disease	5.71e-05	0.000481	CcSEcCtD
Mirtazapine—Nausea—Salbutamol—chronic obstructive pulmonary disease	5.68e-05	0.000478	CcSEcCtD
Mirtazapine—Discomfort—Prednisolone—chronic obstructive pulmonary disease	5.65e-05	0.000476	CcSEcCtD
Mirtazapine—Hallucination—Prednisone—chronic obstructive pulmonary disease	5.58e-05	0.00047	CcSEcCtD
Mirtazapine—Oedema—Prednisolone—chronic obstructive pulmonary disease	5.48e-05	0.000461	CcSEcCtD
Mirtazapine—Shock—Prednisolone—chronic obstructive pulmonary disease	5.39e-05	0.000454	CcSEcCtD
Mirtazapine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	5.35e-05	0.00045	CcSEcCtD
Mirtazapine—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	5.3e-05	0.000446	CcSEcCtD
Mirtazapine—Eye disorder—Prednisone—chronic obstructive pulmonary disease	5.24e-05	0.000441	CcSEcCtD
Mirtazapine—Angiopathy—Prednisone—chronic obstructive pulmonary disease	5.09e-05	0.000428	CcSEcCtD
Mirtazapine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	5.01e-05	0.000422	CcSEcCtD
Mirtazapine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	4.96e-05	0.000417	CcSEcCtD
Mirtazapine—Alopecia—Prednisone—chronic obstructive pulmonary disease	4.96e-05	0.000417	CcSEcCtD
Mirtazapine—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	4.92e-05	0.000414	CcSEcCtD
Mirtazapine—Mental disorder—Prednisone—chronic obstructive pulmonary disease	4.91e-05	0.000414	CcSEcCtD
Mirtazapine—Malnutrition—Prednisone—chronic obstructive pulmonary disease	4.88e-05	0.000411	CcSEcCtD
Mirtazapine—Pain—Prednisolone—chronic obstructive pulmonary disease	4.69e-05	0.000395	CcSEcCtD
Mirtazapine—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	4.53e-05	0.000381	CcSEcCtD
Mirtazapine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	4.52e-05	0.00038	CcSEcCtD
Mirtazapine—Anaemia—Prednisone—chronic obstructive pulmonary disease	4.51e-05	0.00038	CcSEcCtD
Mirtazapine—Agitation—Prednisone—chronic obstructive pulmonary disease	4.49e-05	0.000378	CcSEcCtD
Mirtazapine—Malaise—Prednisone—chronic obstructive pulmonary disease	4.4e-05	0.000371	CcSEcCtD
Mirtazapine—Vertigo—Prednisone—chronic obstructive pulmonary disease	4.39e-05	0.000369	CcSEcCtD
Mirtazapine—Syncope—Prednisone—chronic obstructive pulmonary disease	4.38e-05	0.000368	CcSEcCtD
Mirtazapine—Urticaria—Prednisolone—chronic obstructive pulmonary disease	4.36e-05	0.000367	CcSEcCtD
Mirtazapine—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	4.29e-05	0.000361	CcSEcCtD
Mirtazapine—Convulsion—Prednisone—chronic obstructive pulmonary disease	4.23e-05	0.000356	CcSEcCtD
Mirtazapine—Hypertension—Prednisone—chronic obstructive pulmonary disease	4.22e-05	0.000355	CcSEcCtD
Mirtazapine—Arthralgia—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.00035	CcSEcCtD
Mirtazapine—Myalgia—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.00035	CcSEcCtD
Mirtazapine—Anxiety—Prednisone—chronic obstructive pulmonary disease	4.14e-05	0.000349	CcSEcCtD
Mirtazapine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	4.13e-05	0.000347	CcSEcCtD
Mirtazapine—Discomfort—Prednisone—chronic obstructive pulmonary disease	4.11e-05	0.000346	CcSEcCtD
Mirtazapine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	4.04e-05	0.00034	CcSEcCtD
Mirtazapine—Oedema—Prednisone—chronic obstructive pulmonary disease	3.98e-05	0.000335	CcSEcCtD
Mirtazapine—Infection—Prednisone—chronic obstructive pulmonary disease	3.96e-05	0.000333	CcSEcCtD
Mirtazapine—Shock—Prednisone—chronic obstructive pulmonary disease	3.92e-05	0.00033	CcSEcCtD
Mirtazapine—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	3.91e-05	0.000329	CcSEcCtD
Mirtazapine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	3.89e-05	0.000327	CcSEcCtD
Mirtazapine—Skin disorder—Prednisone—chronic obstructive pulmonary disease	3.87e-05	0.000326	CcSEcCtD
Mirtazapine—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	3.85e-05	0.000324	CcSEcCtD
Mirtazapine—Anorexia—Prednisone—chronic obstructive pulmonary disease	3.8e-05	0.00032	CcSEcCtD
Mirtazapine—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	3.63e-05	0.000306	CcSEcCtD
Mirtazapine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	3.63e-05	0.000305	CcSEcCtD
Mirtazapine—Insomnia—Prednisone—chronic obstructive pulmonary disease	3.6e-05	0.000303	CcSEcCtD
Mirtazapine—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	3.58e-05	0.000301	CcSEcCtD
Mirtazapine—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	3.51e-05	0.000295	CcSEcCtD
Mirtazapine—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	3.46e-05	0.000292	CcSEcCtD
Mirtazapine—Rash—Prednisolone—chronic obstructive pulmonary disease	3.46e-05	0.000291	CcSEcCtD
Mirtazapine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	3.45e-05	0.000291	CcSEcCtD
Mirtazapine—Fatigue—Prednisone—chronic obstructive pulmonary disease	3.44e-05	0.000289	CcSEcCtD
Mirtazapine—Headache—Prednisolone—chronic obstructive pulmonary disease	3.44e-05	0.000289	CcSEcCtD
Mirtazapine—Constipation—Prednisone—chronic obstructive pulmonary disease	3.41e-05	0.000287	CcSEcCtD
Mirtazapine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	3.28e-05	0.000276	CcSEcCtD
Mirtazapine—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	3.26e-05	0.000274	CcSEcCtD
Mirtazapine—Nausea—Prednisolone—chronic obstructive pulmonary disease	3.26e-05	0.000274	CcSEcCtD
Mirtazapine—Urticaria—Prednisone—chronic obstructive pulmonary disease	3.17e-05	0.000266	CcSEcCtD
Mirtazapine—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.15e-05	0.000265	CcSEcCtD
Mirtazapine—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	3.15e-05	0.000265	CcSEcCtD
Mirtazapine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	2.94e-05	0.000247	CcSEcCtD
Mirtazapine—Asthenia—Prednisone—chronic obstructive pulmonary disease	2.86e-05	0.000241	CcSEcCtD
Mirtazapine—Pruritus—Prednisone—chronic obstructive pulmonary disease	2.82e-05	0.000237	CcSEcCtD
Mirtazapine—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	2.73e-05	0.000229	CcSEcCtD
Mirtazapine—Dizziness—Prednisone—chronic obstructive pulmonary disease	2.64e-05	0.000222	CcSEcCtD
Mirtazapine—Vomiting—Prednisone—chronic obstructive pulmonary disease	2.53e-05	0.000213	CcSEcCtD
Mirtazapine—Rash—Prednisone—chronic obstructive pulmonary disease	2.51e-05	0.000211	CcSEcCtD
Mirtazapine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	2.51e-05	0.000211	CcSEcCtD
Mirtazapine—Headache—Prednisone—chronic obstructive pulmonary disease	2.5e-05	0.00021	CcSEcCtD
Mirtazapine—Nausea—Prednisone—chronic obstructive pulmonary disease	2.37e-05	0.000199	CcSEcCtD
Mirtazapine—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	4.98e-06	8.78e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.97e-06	8.76e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.96e-06	8.73e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.96e-06	8.73e-05	CbGpPWpGaD
Mirtazapine—HTR2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.93e-06	8.69e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.93e-06	8.69e-05	CbGpPWpGaD
Mirtazapine—HRH1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.92e-06	8.67e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.92e-06	8.67e-05	CbGpPWpGaD
Mirtazapine—HRH3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.9e-06	8.64e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.89e-06	8.62e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.89e-06	8.62e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.88e-06	8.61e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.88e-06	8.6e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	4.86e-06	8.56e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.83e-06	8.51e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.82e-06	8.49e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	4.82e-06	8.48e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.8e-06	8.45e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.79e-06	8.44e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.73e-06	8.34e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.71e-06	8.3e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.67e-06	8.23e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.67e-06	8.23e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.66e-06	8.21e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.61e-06	8.12e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.58e-06	8.08e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.56e-06	8.04e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.55e-06	8.02e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—GSTP1—chronic obstructive pulmonary disease	4.55e-06	8.01e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.52e-06	7.97e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	4.51e-06	7.95e-05	CbGpPWpGaD
Mirtazapine—HRH3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.49e-06	7.91e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	4.49e-06	7.9e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—HMOX1—chronic obstructive pulmonary disease	4.48e-06	7.9e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.48e-06	7.89e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.48e-06	7.89e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.47e-06	7.87e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.46e-06	7.86e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.46e-06	7.86e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.46e-06	7.86e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	4.45e-06	7.85e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.45e-06	7.84e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.44e-06	7.82e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.44e-06	7.82e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.38e-06	7.73e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	4.36e-06	7.68e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.36e-06	7.68e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.35e-06	7.67e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.35e-06	7.66e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.27e-06	7.53e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.26e-06	7.5e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	4.2e-06	7.41e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.2e-06	7.4e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.19e-06	7.39e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—GSTM1—chronic obstructive pulmonary disease	4.18e-06	7.36e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Metabolism—ALB—chronic obstructive pulmonary disease	4.18e-06	7.36e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.15e-06	7.31e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.13e-06	7.28e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	4.11e-06	7.25e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.07e-06	7.18e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.05e-06	7.13e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.05e-06	7.13e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Metabolism—NOS3—chronic obstructive pulmonary disease	3.99e-06	7.04e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.99e-06	7.03e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.98e-06	7.01e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.97e-06	7e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.96e-06	6.98e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.96e-06	6.98e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.96e-06	6.98e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.96e-06	6.97e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.93e-06	6.92e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.9e-06	6.87e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	3.9e-06	6.86e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.87e-06	6.83e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.8e-06	6.69e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.79e-06	6.68e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.78e-06	6.66e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.78e-06	6.65e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.77e-06	6.64e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.76e-06	6.63e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.74e-06	6.59e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.73e-06	6.58e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.7e-06	6.52e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.7e-06	6.52e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.68e-06	6.49e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.67e-06	6.46e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.65e-06	6.43e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	3.62e-06	6.38e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.62e-06	6.37e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.61e-06	6.36e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.6e-06	6.34e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.59e-06	6.33e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.58e-06	6.3e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.53e-06	6.22e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.52e-06	6.2e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.51e-06	6.19e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.5e-06	6.16e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	3.48e-06	6.13e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.45e-06	6.08e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.43e-06	6.05e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.43e-06	6.04e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.42e-06	6.02e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.41e-06	6.01e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.4e-06	5.99e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	3.39e-06	5.98e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.36e-06	5.91e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.34e-06	5.89e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.34e-06	5.89e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.33e-06	5.86e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.27e-06	5.77e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.27e-06	5.75e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.25e-06	5.73e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	3.24e-06	5.72e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.22e-06	5.68e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.21e-06	5.66e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.2e-06	5.65e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.2e-06	5.64e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.18e-06	5.6e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	3.18e-06	5.6e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.17e-06	5.59e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.16e-06	5.57e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.13e-06	5.52e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.13e-06	5.51e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.12e-06	5.5e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.12e-06	5.49e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.12e-06	5.49e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.08e-06	5.43e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.07e-06	5.41e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.07e-06	5.4e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.06e-06	5.4e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.06e-06	5.39e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.05e-06	5.37e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.04e-06	5.36e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.03e-06	5.34e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.02e-06	5.32e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.98e-06	5.25e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.98e-06	5.25e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	2.98e-06	5.25e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.98e-06	5.24e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.96e-06	5.22e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.95e-06	5.2e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.93e-06	5.16e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.92e-06	5.15e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.91e-06	5.13e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.91e-06	5.12e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.9e-06	5.1e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.9e-06	5.1e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.89e-06	5.09e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.85e-06	5.03e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	2.84e-06	5.01e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.83e-06	4.99e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.82e-06	4.96e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.81e-06	4.96e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.77e-06	4.88e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.76e-06	4.86e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.76e-06	4.85e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.75e-06	4.85e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	2.71e-06	4.78e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—ALB—chronic obstructive pulmonary disease	2.69e-06	4.74e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.69e-06	4.74e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.68e-06	4.72e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.65e-06	4.66e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.64e-06	4.65e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.62e-06	4.61e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.6e-06	4.58e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.59e-06	4.56e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.58e-06	4.54e-05	CbGpPWpGaD
Mirtazapine—CYP2C8—Metabolism—NOS3—chronic obstructive pulmonary disease	2.58e-06	4.54e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.57e-06	4.52e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.56e-06	4.5e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.54e-06	4.48e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.54e-06	4.47e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.52e-06	4.43e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.51e-06	4.42e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.49e-06	4.38e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.47e-06	4.36e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.46e-06	4.34e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.44e-06	4.3e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.43e-06	4.28e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.43e-06	4.28e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.41e-06	4.24e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.41e-06	4.24e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.41e-06	4.24e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.39e-06	4.22e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.39e-06	4.21e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.39e-06	4.2e-05	CbGpPWpGaD
Mirtazapine—OPRK1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.36e-06	4.15e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.34e-06	4.13e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.34e-06	4.12e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.33e-06	4.11e-05	CbGpPWpGaD
Mirtazapine—HTR7—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.32e-06	4.09e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.32e-06	4.08e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.29e-06	4.03e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.29e-06	4.03e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.28e-06	4.02e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.27e-06	4e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.24e-06	3.95e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.24e-06	3.94e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.23e-06	3.92e-05	CbGpPWpGaD
Mirtazapine—DRD4—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.22e-06	3.91e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.21e-06	3.89e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.21e-06	3.89e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	2.19e-06	3.86e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.18e-06	3.85e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.18e-06	3.84e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.17e-06	3.82e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.16e-06	3.8e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.15e-06	3.79e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.14e-06	3.78e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.13e-06	3.75e-05	CbGpPWpGaD
Mirtazapine—HTR2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.12e-06	3.74e-05	CbGpPWpGaD
Mirtazapine—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	2.11e-06	3.73e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.1e-06	3.71e-05	CbGpPWpGaD
Mirtazapine—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	2.1e-06	3.69e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2e-06	3.53e-05	CbGpPWpGaD
Mirtazapine—DRD3—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.97e-06	3.48e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.97e-06	3.47e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.97e-06	3.47e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.96e-06	3.46e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.96e-06	3.46e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	1.95e-06	3.44e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.93e-06	3.41e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.93e-06	3.4e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.93e-06	3.4e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.92e-06	3.39e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.89e-06	3.34e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.88e-06	3.31e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	1.87e-06	3.3e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.87e-06	3.29e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.82e-06	3.2e-05	CbGpPWpGaD
Mirtazapine—ADRB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.8e-06	3.17e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	1.79e-06	3.16e-05	CbGpPWpGaD
Mirtazapine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.79e-06	3.16e-05	CbGpPWpGaD
Mirtazapine—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.76e-06	3.1e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	1.76e-06	3.1e-05	CbGpPWpGaD
Mirtazapine—HTR1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.72e-06	3.03e-05	CbGpPWpGaD
Mirtazapine—HTR2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.71e-06	3.02e-05	CbGpPWpGaD
Mirtazapine—ADRA2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.66e-06	2.93e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.65e-06	2.91e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.62e-06	2.86e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.62e-06	2.85e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.59e-06	2.8e-05	CbGpPWpGaD
Mirtazapine—DRD2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.51e-06	2.66e-05	CbGpPWpGaD
Mirtazapine—HTR2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.49e-06	2.62e-05	CbGpPWpGaD
Mirtazapine—HRH1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.48e-06	2.61e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.48e-06	2.6e-05	CbGpPWpGaD
Mirtazapine—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.45e-06	2.56e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	1.45e-06	2.55e-05	CbGpPWpGaD
Mirtazapine—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	1.38e-06	2.44e-05	CbGpPWpGaD
Mirtazapine—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.35e-06	2.38e-05	CbGpPWpGaD
